External reports (aggregated public sources), Value Investors Club

Value Investors Club

External reports (aggregated public sources)

Equity Bottom-Up

<ul><li>ACRC is a biotech pharma micro-cap company trading below its net cash value</li><li>Downsized workforce after a failed phase 2 trial, CEO and CMO left prompting strategic evaluation</li><li>Activist investors involved, potential for monetization of stakes to benefit shareholders.</li></ul><p><em>This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.</em></p>

ACRC is a biotech pharma micro-cap company trading below its net cash valueDownsized workforce after a failed phase 2 trial, CEO and CMO left prompting strategic evaluationActivist investors involved, potential for monetization of stakes to benefit shareholders.This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Aclaris Therapeutics Inc (ACRS) - Sunday, Mar 24, 2024

Independent Research, Turtles all the way down

Turtles all the way down

Independent Research

Writing short articles about mis-priced boring stocks around the world.

<ul><li>First I sold my Berry Global (BERY) shares (mentioned here a few days ago ) and my opinion on the spin-off transaction went from being neutral to slightly positive to neutral to slightly negative.</li><li>Probably should have looked into it deeper, but I got a large backlog of stocks to look at right now.</li><li>So what I will do is I will wait until after the spin-off before entering a position. I will be away anyway when the spin off begins trading, so I will not have the option to sell it right away, which I also don’t like.</li></ul>

First I sold my Berry Global (BERY) shares (mentioned here a few days ago ) and my opinion on the spin-off transaction went from being neutral to slightly positive to neutral to slightly negative.Probably should have looked into it deeper, but I got a large backlog of stocks to look at right now.So what I will do is I will wait until after the spin-off before entering a position. I will be away anyway when the spin off begins trading, so I will not have the option to sell it right away, which I also don’t like.

United States

Aclaris Therapeutics, Inc. operates as a clinical-stage specialty pharmaceutical company. The Company focuses on identifying, developing, and commercialization topical drugs to address significant unmet needs in dermatology. Aclaris Therapeutics offers a topical therapy for the treatment of seborrheic keratosis and other verrucoid lesions of the skin.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Aclaris Therapeutics (ACRS US)

Aclaris Therapeutics Inc (ACRS) - Sunday, Mar 24, 2024

ACRC is a biotech pharma micro-cap company trading below its net cash value. Downsized workforce after a failed phase 2 trial, CEO and CMO left...

Value Investors Club

Closing 5 ideas

First I sold my Berry Global (BERY) shares (mentioned here a few days ago ) and my opinion on the spin-off transaction went from being neutral to...

Turtles all the way down

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)